A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
Solid Tumors
DRUG: BIIB015
To evaluate safety, ongoing|To determine the maximum-tolerated dose (MTD), ongoing
To evaluate pharmacokinetics (PK), ongoing|To evaluate clinical activity, ongoing
Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.